Skip Navigation
Skip to contents



30 results

Treatment of Pulmonary Tumor Embolism from Choriocarcinoma: Extracorporeal Membrane Oxygenation as a Bridge through Chemotherapy

Chung JH, Yeo HJ, Cho HM, Jang JO, Ye BM, Yoon G, Shin DH, Kim D, Cho WH

  • Cancer Res Treat.
  • 2017 Jan;49(1):279-282.
  • doi: 10.4143/crt.2016.125
A 22-year-old woman with a 1-month history of shortness of breath that was treated as a case of tuberculosis and pulmonary embolism was referred to the authors’ hospital. Because of...
Human Herpesvirus 8–Unrelated Primary Effusion Lymphoma–Like Lymphoma in an Elderly Korean Patient with a Good Response to Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisolone

Shin J, Lee JO, Choe JY, Bang SM, Lee JS

  • Cancer Res Treat.
  • 2017 Jan;49(1):274-278.
  • doi: 10.4143/crt.2016.076
Primary effusion lymphoma (PEL) is a rare type of non-Hodgkin’s lymphoma arising from a B-cell lineage characterized by the formation of malignant effusion in body cavities without evidence of a...
Adjuvant Chemotherapy for Advanced Gastric Cancer in Elderly and Non-elderly Patients: Meta-Analysis of Randomized Controlled Trials

Chang SH, Kim SN, Choi HJ, Park M, Kim RB, Go SI, Lee WS

  • Cancer Res Treat.
  • 2017 Jan;49(1):263-273.
  • doi: 10.4143/crt.2016.054
PURPOSE: This study evaluated the benefits of adjuvant chemotherapy on elderly patients with advanced gastric cancer (AGC) using meta-analysis of well-designed randomized controlled clinical studies. MATERIALS AND METHODS: PubMed, Embase, and...
Irinotecan Monotherapy Versus Irinotecan-Based Combination as Second-Line Chemotherapy in Advanced Gastric Cancer: A Meta-Analysis

Cho YH, Yoon SY, Kim SN

  • Cancer Res Treat.
  • 2017 Jan;49(1):255-262.
  • doi: 10.4143/crt.2015.452
PURPOSE: A meta-analysis was conducted to examine the question of whether combination regimens are more effective than monotherapy as a second-line chemotherapy in advanced gastric cancer. MATERIALS AND METHODS: The MEDLINE...
Overexpression of PD-L1 and PD-L2 Is Associated with Poor Prognosis in Patients with Hepatocellular Carcinoma

Jung HI, Jeong D, Ji S, Ahn TS, Bae SH, Chin S, Chung JC, Kim HC, Lee MS, Baek MJ

  • Cancer Res Treat.
  • 2017 Jan;49(1):246-254.
  • doi: 10.4143/crt.2016.066
PURPOSE: Hepatocellular carcinoma (HCC) is one of the most aggressive malignancies. Recently, the overexpression of programmed cell death 1 (PD-1) and PD-1 ligand 1 (PD-L1) has been shown to correlate...
Studying the Effect of Downregulating Autophagy-Related Gene LC3 on TLR3 Apoptotic Pathway Mediated by dsRNA in Hepatocellular Carcinoma Cells

Wang G, Zhang M, Li Y, Zhou J, Chen L

  • Cancer Res Treat.
  • 2017 Jan;49(1):230-245.
  • doi: 10.4143/crt.2015.506
PURPOSE: The purpose of this study is to examine the role of the double-stranded RNA (dsRNA) activated Toll–interleukin-1 receptor domain-containing adaptor inducing interferon β (TRIF) signal pathway in triggering apoptosis...
Anti-cancer Effects of a Novel Quinoline Derivative 83b1 on Human Esophageal Squamous Cell Carcinoma through Down-Regulation of COX-2 mRNA and PGEâ‚‚

Pun IH, Chan D, Chan SH, Chung PY, Zhou YY, Law S, Lam AK, Chui CH, Chan AS, Lam KH, Tang JC

  • Cancer Res Treat.
  • 2017 Jan;49(1):219-229.
  • doi: 10.4143/crt.2016.190
PURPOSE: 83b1 is a novel quinoline derivative that has been shown to inhibit cancer growth in human esophageal squamous cell carcinoma (ESCC). This study was conducted to comprehensively evaluate the...
Clinicopathological Features of Low-Grade Thyroid-like Nasopharyngeal Papillary Adenocarcinoma

Li M, Wei J, Yao X, Wang C

  • Cancer Res Treat.
  • 2017 Jan;49(1):213-218.
  • doi: 10.4143/crt.2016.195
PURPOSE: Primary low-grade thyroid-like papillary adenocarcinomas are extremely rare neoplasms that generally originate in the nasopharynx. Here, we describe a novel case of a 15-year-old Chinese girl who was diagnosed...
Analysis of the Clinicopathological Characteristics of Gastric Cancer in Extremely Old Patients

Sohn IW, Jung DH, Kim JH, Chung HS, Park JC, Shin SK, Lee SK, Lee YC

  • Cancer Res Treat.
  • 2017 Jan;49(1):204-212.
  • doi: 10.4143/crt.2016.163
PURPOSE: Gastric cancer is the third-leading cause of cancer-related death in Korea. As the Korean population is ageing, the number of extremely old patients with this disease is increasing. This...
Concurrent Chemoradiotherapy with Temozolomide Followed by Adjuvant Temozolomide for Newly Diagnosed Glioblastoma Patients: A Retrospective Multicenter Observation Study in Korea

Kim BS, Seol HJ, Nam DH, Park CK, Kim IH, Kim TM, Kim JH, Cho YH, Yoon SM, Chang JH, Kang SG, Kim EH, Suh CO, Jung TY, Lee KH, Kim CY, Kim IA, Hong CK, Yoo H, Kim JH, Kang SH, Kang MK, Kim EY, Kim SH, Chung DS, Hwang SC, Song JH, Cho SJ, Lee SI, Lee YS, Ahn KJ, Kim SH, Lim DH, Gwak HS, Lee SH, Hong YK

  • Cancer Res Treat.
  • 2017 Jan;49(1):193-203.
  • doi: 10.4143/crt.2015.473
PURPOSE: The purpose of this study was to investigate the feasibility and survival benefits of combined treatment with radiotherapy and adjuvant temozolomide (TMZ) in a Korean sample. MATERIALS AND METHODS: A...
Rare Incidence of ROS1 Rearrangement in Cholangiocarcinoma

Lim SM, Yoo JE, Lim KH, Meng Tai D, Cho BC, Park YN

  • Cancer Res Treat.
  • 2017 Jan;49(1):185-192.
  • doi: 10.4143/crt.2015.497
PURPOSE: The recent discovery and characterization of an oncogenic ROS1 gene rearrangement has raised significant interest because small molecule inhibitors are effective in these tumors. The aim of this study...
Tumor Stage-Related Role of Radiotherapy in Patients with an External Auditory Canal and Middle Ear Carcinoma

Choi J, Kim SH, Koh YW, Choi EC, Lee CG, Keum KC

  • Cancer Res Treat.
  • 2017 Jan;49(1):178-184.
  • doi: 10.4143/crt.2016.165
PURPOSE: The purpose of this study was to evaluate the clinical outcomes of patients treated with radiotherapy (RT) for a carcinoma of the external auditory canal (EAC) and middle ear. MATERIALS...
Optimal Adjuvant Treatment for Curatively Resected Thoracic Esophageal Squamous Cell Carcinoma: A Radiotherapy Perspective

Kim KH, Chang JS, Cha JH, Lee IJ, Kim DJ, Cho BC, Park KR, Lee CG

  • Cancer Res Treat.
  • 2017 Jan;49(1):168-177.
  • doi: 10.4143/crt.2016.142
PURPOSE: The purpose of this study was to evaluate the benefits of adjuvant treatment for curatively resected thoracic esophageal squamous cell carcinoma (ESCC) and determine the optimal adjuvant treatments. MATERIALS AND...
Paired Primary and Metastatic Tumor Analysis of Somatic Mutations in Synchronous and Metachronous Colorectal Cancer

Kim KP, Kim JE, Hong YS, Ahn SM, Chun SM, Hong SM, Jang SJ, Yu CS, Kim JC, Kim TW

  • Cancer Res Treat.
  • 2017 Jan;49(1):161-167.
  • doi: 10.4143/crt.2015.490
PURPOSE: Although the mutation status of KRAS is highly concordant in primary and metastatic lesions, it has not been generalized to other major pathway genes. MATERIALS AND METHODS: In this study,...
Gastric Carcinogenesis in the miR-222/221 Transgenic Mouse Model

Choi B, Yu J, Han TS, Kim YK, Hur K, Kang BC, Kim WH, Kim DY, Lee HJ, Kim VN, Yang HK

  • Cancer Res Treat.
  • 2017 Jan;49(1):150-160.
  • doi: 10.4143/crt.2015.462
PURPOSE: MicroRNAs (miRNAs) regulate various cellular functions, including development, cell proliferation, apoptosis, and tumorigenesis. Different signatures associated with various tissue types, diagnosis, progression, prognosis, staging, and treatment response have been...
Reactive Oxygen Species Modulator 1 (Romo1) Predicts Poor Outcomes in Advanced Non-small Cell Lung Cancer Patients Treated with Platinum-Based Chemotherapy

Lee SH, Choi SI, Lee JS, Kim CH, Jung WJ, Lee EJ, Min KH, Hur GY, Lee SH, Lee SY, Kim JH, Lee SY, Shin C, Shim JJ, Kang KH, In KH

  • Cancer Res Treat.
  • 2017 Jan;49(1):141-149.
  • doi: 10.4143/crt.2016.133
PURPOSE: Reactive oxygen species modulator 1 (Romo1) is a key mediator of intracellular reactive oxygen species production. However, examination of the clinical usefulness of Romo1 in cancers has been limited....
Post-bevacizumab Clinical Outcomes and the Impact of Early Discontinuation of Bevacizumab in Patients with Recurrent Malignant Glioma

Cha Y, Kim YJ, Lee SH, Kim TM, Choi SH, Kim DW, Park CK, Kim IH, Kim JH, Kim E, Choi B, Kim CY, Kim IA, Heo DS

  • Cancer Res Treat.
  • 2017 Jan;49(1):129-140.
  • doi: 10.4143/crt.2015.466
PURPOSE: Bevacizumab±irinotecan is effective for treatment of recurrent malignant gliomas. However, the optimal duration of treatment has not been established. MATERIALS AND METHODS: Ninety-four consecutive patients with recurrent malignant glioma who...
Use of a Combined Gene Expression Profile in Implementing a Drug Sensitivity Predictive Model for Breast Cancer

Zhang X, Cha IH, Kim KY

  • Cancer Res Treat.
  • 2017 Jan;49(1):116-128.
  • doi: 10.4143/crt.2016.085
PURPOSE: Chemotherapy targets all rapidly growing cells, not only cancer cells, and thus is often associated with unpleasant side effects. Therefore, examination of the chemosensitivity based on genotypes is needed...
Curative Resection for Metachronous Pulmonary Metastases from Colorectal Cancer: Analysis of Survival Rates and Prognostic Factors

Ihn MH, Kim DW, Cho S, Oh HK, Jheon S, Kim K, Shin E, Lee HS, Chung JH, Kang SB

  • Cancer Res Treat.
  • 2017 Jan;49(1):104-115.
  • doi: 10.4143/crt.2015.367
PURPOSE: Prognostic factors in patients with pulmonary metastases (PM) from colorectal cancer (CRC) are still controversial. This study assessed oncologic outcomes and prognostic factors in patients with metachronous PM from...
Comparison of Total Body Irradiation (TBI) Conditioning with Non-TBI for Autologous Stem Cell Transplantation in Newly Diagnosed or Relapsed Mature T- and NK-Cell Non-Hodgkin Lymphoma

Maeng CH, Ko YH, Lim DH, Kang ES, Choi JY, Kim WS, Kim SJ

  • Cancer Res Treat.
  • 2017 Jan;49(1):92-103.
  • doi: 10.4143/crt.2015.476
PURPOSE: This retrospective study was conducted for comparison of survival outcomes and toxicities of autologous stem cell transplantation (ASCT) based on the use of total body irradiation (TBI) as a...

Go to Top

Copyright © 2020 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: